Reply to “mTOR inhibitor-related pulmonary toxicity; incidence even higher”

By Palazzo Antonella   Iacovelli Roberto   Cortesi Enrico  

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1235-1235

Informa Healthcare

Access to resources Recommend Favorite

mTOR inhibitor-related pulmonary toxicity; incidence even higher

By Willemsen Anna E. C. A. B.   van Herpen Carla M. L.  

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1234-1234

Informa Healthcare

Access to resources Recommend Favorite

Raltitrexed in the treatment of elderly patients with advanced colorectal cancer - an active and low toxicity regimen

By Feliu J.   Mel J.R.   Camps C.   Escudero P.   Aparicio J.   Menendez D.   Garca Giron C.   Rodriguez M.R.   Sanchez J.J.   Gonzalez Baron M.   on behalf of Oncopaz Cooperative Group Associated Hospitals  

European Journal of Cancer, Vol. 38, Iss. 9, 2002-06 ,pp. : 1204-1211

Elsevier

Access to resources Recommend Favorite

Pulmonary toxicity in patients receiving docetaxel chemotherapy

By Yumuk Perran  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1381-1388

Humana Press, Inc

Access to resources Recommend Favorite

Management of skin toxicity related to the use of imatinib mesylate

By Scott Lucy C.  

Sarcoma, Vol. 9, Iss. 3-4, 2005-09 ,pp. : 157-160

Informa Healthcare

Access to resources Recommend Favorite